SBS Stock Overview
Designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Stratec SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €29.00 |
| 52 Week High | €48.60 |
| 52 Week Low | €26.05 |
| Beta | 0.26 |
| 1 Month Change | 9.64% |
| 3 Month Change | -33.94% |
| 1 Year Change | -32.56% |
| 3 Year Change | -78.10% |
| 5 Year Change | -53.67% |
| Change since IPO | 457.37% |
Recent News & Updates
With A 25% Price Drop For Stratec SE (ETR:SBS) You'll Still Get What You Pay For
Nov 09
Returns At Stratec (ETR:SBS) Appear To Be Weighed Down
Oct 26Recent updates
With A 25% Price Drop For Stratec SE (ETR:SBS) You'll Still Get What You Pay For
Nov 09Returns At Stratec (ETR:SBS) Appear To Be Weighed Down
Oct 26Here's Why It's Unlikely That Stratec SE's (ETR:SBS) CEO Will See A Pay Rise This Year
May 11Stratec's (ETR:SBS) Dividend Will Be Reduced To €0.55
Apr 11Stratec SE Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next
Apr 01Stratec (ETR:SBS) Has Announced That Its Dividend Will Be Reduced To €0.55
Mar 28Is There An Opportunity With Stratec SE's (ETR:SBS) 36% Undervaluation?
Dec 21Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement
Nov 03We Think Stratec (ETR:SBS) Is Taking Some Risk With Its Debt
Oct 19Return Trends At Stratec (ETR:SBS) Aren't Appealing
Jul 12Stratec SE (ETR:SBS) Shares Could Be 43% Below Their Intrinsic Value Estimate
Jun 27Is Stratec (ETR:SBS) Using Too Much Debt?
May 25Stratec's (ETR:SBS) Upcoming Dividend Will Be Larger Than Last Year's
Apr 02The Returns At Stratec (ETR:SBS) Aren't Growing
Jan 28Calculating The Fair Value Of Stratec SE (ETR:SBS)
Jan 12Is Stratec (ETR:SBS) A Risky Investment?
Oct 26Returns On Capital At Stratec (ETR:SBS) Have Stalled
Oct 11Stratec (ETR:SBS) Has A Pretty Healthy Balance Sheet
Jul 23Should You Be Adding Stratec (ETR:SBS) To Your Watchlist Today?
Jul 07Stratec's (ETR:SBS) Shareholders Will Receive A Bigger Dividend Than Last Year
May 12Stratec (ETR:SBS) Has Announced That It Will Be Increasing Its Dividend To €0.95
Apr 28Analysts Are Updating Their Stratec SE (ETR:SBS) Estimates After Its Annual Results
Apr 03Stratec's (ETR:SBS) Dividend Will Be Increased To €0.95
Apr 02These 4 Measures Indicate That Stratec (ETR:SBS) Is Using Debt Reasonably Well
Mar 13Stratec (ETR:SBS) Is Doing The Right Things To Multiply Its Share Price
Feb 12Do Stratec's (ETR:SBS) Earnings Warrant Your Attention?
Jan 27We Think Stratec (ETR:SBS) Can Stay On Top Of Its Debt
Dec 05Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement
Nov 02Do Stratec's (ETR:SBS) Earnings Warrant Your Attention?
Oct 18Is Stratec (ETR:SBS) Using Too Much Debt?
Sep 03Shareholder Returns
| SBS | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -13.6% | -2.9% | -2.6% |
| 1Y | -32.6% | -8.5% | 6.9% |
Return vs Industry: SBS underperformed the German Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: SBS underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| SBS volatility | |
|---|---|
| SBS Average Weekly Movement | 7.7% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SBS's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: SBS's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 1,462 | Marcus Wolfinger | www.stratec.com |
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018.
Stratec SE Fundamentals Summary
| SBS fundamental statistics | |
|---|---|
| Market cap | €352.52m |
| Earnings (TTM) | €10.01m |
| Revenue (TTM) | €250.54m |
35.2x
P/E Ratio1.4x
P/S RatioIs SBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBS income statement (TTM) | |
|---|---|
| Revenue | €250.54m |
| Cost of Revenue | €182.78m |
| Gross Profit | €67.75m |
| Other Expenses | €57.74m |
| Earnings | €10.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 27, 2025
| Earnings per share (EPS) | 0.82 |
| Gross Margin | 27.04% |
| Net Profit Margin | 4.00% |
| Debt/Equity Ratio | 67.0% |
How did SBS perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield67%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:06 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Stratec SE is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Volker Braun | Bankhaus Lampe KG |
| Odysseas Manesiotis | Berenberg |
| Scott Bardo | Berenberg |